The European Medicines Agency has recommended the refusal of the marketing authorisation for Elzonris, a medicine intended for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
The Agency issued its opinion on 23 July 2020. The company that applied for authorisation, Stemline Therapeutics B.V, may ask for re-examination of the opinion within 15 days of receiving the opinion.
|Agency product number||
|International non-proprietary name (INN) or common name||
|Date opinion adopted||